Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Athersys Inc (ATHX)

Athersys Inc (ATHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,409
  • Shares Outstanding, K 263,934
  • Annual Sales, $ 5,510 K
  • Annual Income, $ -86,960 K
  • 60-Month Beta -1.26
  • Price/Sales 13.48
  • Price/Cash Flow N/A
  • Price/Book 209.62
Trade ATHX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.35
  • Most Recent Earnings -0.09 on 05/06/22
  • Next Earnings Date 08/11/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 646.77% ( -178.57%)
  • Historical Volatility 195.68%
  • IV Percentile 97%
  • IV Rank 74.61%
  • IV High 841.44% on 06/21/22
  • IV Low 74.65% on 08/25/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 38
  • Volume Avg (30-Day) 367
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 40,386
  • Open Int (30-Day) 41,512

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.03
  • Number of Estimates 1
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1708 +41.33%
on 07/26/22
0.3880 -37.78%
on 07/28/22
+0.0374 (+18.33%)
since 07/15/22
3-Month
0.1708 +41.33%
on 07/26/22
0.7770 -68.93%
on 05/19/22
-0.3414 (-58.58%)
since 05/13/22
52-Week
0.1708 +41.33%
on 07/26/22
1.8100 -86.66%
on 09/02/21
-1.3886 (-85.19%)
since 08/13/21

Most Recent Stories

More News
Athersys, Inc. Announces $12 Million Registered Direct Offering

Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 48,000,000 shares...

ATHX : 0.2457 (-3.80%)
Athersys (ATHX) Q2 2022 Earnings Call Transcript

ATHX earnings call for the period ending June 30, 2022.

ATHX : 0.2457 (-3.80%)
Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update

Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update.

ATHX : 0.2457 (-3.80%)
Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications

Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory...

ATHX : 0.2457 (-3.80%)
Athersys Appoints Kasey Rosado as Interim Chief Financial Officer

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces today its engagement with Ankura Consulting Group, LLC and...

ATHX : 0.2457 (-3.80%)
Athersys to Host Second Quarter Financial Results Call

Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022, and will host a conference call shortly thereafter...

ATHX : 0.2457 (-3.80%)
Athersys and Aspire Capital Fund Terminate Relationship

Athersys, Inc. (Nasdaq: ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated. The Company continues to evaluate alternative financing...

ATHX : 0.2457 (-3.80%)
Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures

Athersys, Inc. (Nasdaq: ATHX) today announced the Company’s slate of director candidates for its 2022 Annual Meeting of Stockholders being held on Thursday, July 28, 2022, at 8:30 a.m. ET. As previously...

ATHX : 0.2457 (-3.80%)
Athersys Postpones Annual Meeting of Stockholders

Athersys, Inc. (Nasdaq: ATHX) today announced the postponement of its Annual Meeting of Stockholders, initially scheduled for Wednesday, June 15, 2022, at 8:30 a.m. ET. The Annual Meeting is now scheduled...

ATHX : 0.2457 (-3.80%)
Athersys Hosting KOL Panel Event to Discuss TREASURE Data

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a panel discussion with leading neurology...

ATHX : 0.2457 (-3.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and...

See More

Key Turning Points

3rd Resistance Point 0.2988
2nd Resistance Point 0.2844
1st Resistance Point 0.2699
Last Price 0.2457
1st Support Level 0.2410
2nd Support Level 0.2266
3rd Support Level 0.2121

See More

52-Week High 1.8100
Fibonacci 61.8% 1.1838
Fibonacci 50% 0.9904
Fibonacci 38.2% 0.7970
Last Price 0.2457
52-Week Low 0.1708

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar